Delishaj D, Fumagalli IC, Ursino S, Cristaudo A, Colangelo F, Stefanelli A, Alghisi A, De Nobili G, D’Amico R, Cocchi A, Ardizzoia A, Soatti CP. Neoadjuvant radiotherapy dose escalation for locally advanced rectal cancers in the new era of radiotherapy: A review of literature. World J Clin Cases 2021; 9(30): 9077-9089 [PMID: 34786390 DOI: 10.12998/wjcc.v9.i30.9077]
Corresponding Author of This Article
Durim Delishaj, MD, Doctor, Department of Radiation Oncology, Alessandro Manzoni Hospital, Via Dell’Eremo, 9/11, Lecco 23900, Italy. d.delishaj@asst-lecco.it
Research Domain of This Article
Oncology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 26, 2021; 9(30): 9077-9089 Published online Oct 26, 2021. doi: 10.12998/wjcc.v9.i30.9077
Neoadjuvant radiotherapy dose escalation for locally advanced rectal cancers in the new era of radiotherapy: A review of literature
Durim Delishaj, Ilaria Costanza Fumagalli, Stefano Ursino, Agostino Cristaudo, Francesco Colangelo, Antonio Stefanelli, Alessandro Alghisi, Giuseppe De Nobili, Romerai D’Amico, Alessandra Cocchi, Antonio Ardizzoia, Carlo Pietro Soatti
Durim Delishaj, Francesco Colangelo, Alessandro Alghisi, Giuseppe De Nobili, Romerai D’Amico, Alessandra Cocchi, Carlo Pietro Soatti, Department of Radiation Oncology, Alessandro Manzoni Hospital, Lecco 23900, Italy
Ilaria Costanza Fumagalli, Department of Radiation Oncology, San Donato Hospital, Milan 20097, Italy
Stefano Ursino, Department of Radiation Oncology, Santa Chiara University Hospital, Pisa 56126, Italy
Agostino Cristaudo, Royal Preston Hospital, Lancashire Teaching Hospital- NHS Tust, Preston PR2 9HT, United Kingdom
Antonio Stefanelli, Department of Radiation Oncology, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara 44124, Italy
Antonio Ardizzoia, Department of Clinical Oncology, Alessandro Manzoni Hospital, Lecco 23900, Italy
Author contributions: Delishaj D, Ursino S and Fumagalli CI participate on drafting and searching process of the review; Fumagalli CI, Colangero F, D’Amico R, Alghisi A and De Nobili G contributed on data extraction and screening process of the review; Cocchi A and Stefanelli A revised the review critically for important intellectual content improving scientific value of the manuscript; Cristaudo A proceeded correcting all English grammar errors, improving the scientific value of review and doing the text more fluently and easier to understand from readers and reviewers; Soatti CP and Ardizzoia A give final approval of the review to be submitted and any revised version of manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Durim Delishaj, MD, Doctor, Department of Radiation Oncology, Alessandro Manzoni Hospital, Via Dell’Eremo, 9/11, Lecco 23900, Italy. d.delishaj@asst-lecco.it
Received: April 14, 2021 Peer-review started: April 14, 2021 First decision: June 3, 2021 Revised: June 27, 2021 Accepted: September 14, 2021 Article in press: September 14, 2021 Published online: October 26, 2021 Processing time: 189 Days and 19.3 Hours
Core Tip
Core Tip: We analyzed the role of neoadjuvant radiotherapy dose escalation for locally advanced rectal cancers (LARC) using innovative radiotherapy techniques. A comprehensive literature search was performed on electronic database with a period limit from January 2009 to December 2020. According to PRISMA Group (2009) screening process only studies using equivalent dose 2 Gy fraction (EQD2) ≥ 54 Gy and Volumetric Modulated Arc Therapy, image-guided radiotherapy or image-guided radiotherapy techniques were included for the review. Neoadjuvant radiotherapy dose escalation using innovative techniques is safe for LARC with acceptable acute toxicity, achieving higher pathological complete response compared to standard treatment. EQD2 doses > 58.9 Gy with a BED > 70.7 Gy was associated with higher rate of surgical complications.
